Fatty Liver Disease and Gut Microbiota: A Comprehensive Update
Open Access
- 28 December 2018
- journal article
- review article
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 7 (1), 1-5
- https://doi.org/10.14218/jcth.2018.00008
Abstract
Nonalcoholic fatty liver disease (NAFLD) is the accumulation of fat in the liver in the absence of secondary causes. NAFLD is a multifactorial disease that results from the interaction of genetic predisposition and metabolic, inflammatory and environmental factors. Among these factors, dysregulation of gut microbiome has been linked to the development of fatty liver disease. The microbiome composition can be modified by dietary habits leading to gut microbiome dysbiosis, especially when a diet is rich in saturated fats, animal products and fructose sugars. Different species of bacteria in the gut metabolize nutrients differently, triggering different pathways that contribute to the accumulation of fat within the liver and triggering inflammatory cascades that promote liver damage. In this review, we summarize the current understanding of the roles of gut microbiota in mediating NAFLD development and discuss possible gut microbiota-targeted therapies for NAFLD. We summarize experimental and clinical evidence, and draw conclusions on the therapeutic potential of manipulating gut microbiota to decrease the incidence and prevalence of fatty liver disease.Keywords
This publication has 44 references indexed in Scilit:
- Molecular Characterization of the Fecal Microbiota in Patients with Nonalcoholic Steatohepatitis – A Longitudinal StudyPLOS ONE, 2013
- Microbial conversion of choline to trimethylamine requires a glycyl radical enzymeProceedings of the National Academy of Sciences of the United States of America, 2012
- Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesityNature, 2012
- Association Between Composition of the Human Gastrointestinal Microbiome and Development of Fatty Liver With Choline DeficiencyGastroenterology, 2011
- Composition, variability, and temporal stability of the intestinal microbiota of the elderlyProceedings of the National Academy of Sciences of the United States of America, 2010
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic SteatohepatitisThe New England Journal of Medicine, 2010
- Pathogenesis of non-alcoholic fatty liver diseaseQJM: An International Journal of Medicine, 2009
- Human gut microbes associated with obesityNature, 2006
- An obesity-associated gut microbiome with increased capacity for energy harvestNature, 2006
- Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant miceProceedings of the National Academy of Sciences of the United States of America, 2006